Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp (NASDAQ: LEXX) specializes in enhancing pharmaceutical efficacy through its patented DehydraTECH™ drug delivery platform. This page provides investors and industry professionals with centralized access to official company announcements, research milestones, and strategic developments.
Discover up-to-date information on clinical trials, intellectual property expansions, and partnership agreements. Our curated news collection enables efficient tracking of LEXX’s progress in improving oral bioavailability for GLP-1 medications, antiviral therapies, and cannabinoid-based treatments.
Key updates include regulatory filings, laboratory study results, and licensing agreements that demonstrate Lexaria’s leadership in drug delivery innovation. All content is sourced directly from company communications to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Lexaria’s latest developments in transforming oral medication effectiveness. Check regularly for updates on technology implementations and research breakthroughs that address critical challenges in pharmaceutical administration.
Lexaria Bioscience Corp. has selected InClin, a California-based CRO, to manage its upcoming Phase 1b hypertension study, titled HYPER-H23-1, evaluating the safety and efficacy of its patented DehydraTECH-CBD. The study aims to assess the treatment on 120 patients with Stage 1 and Stage 2 hypertension, following successful FDA pre-IND meeting outcomes. Lexaria plans to file its IND application this summer, anticipating FDA authorization within 60 days. Previous studies indicated that DehydraTECH-CBD significantly reduced blood pressure with no serious adverse events, setting it apart from other CBD formulations. The company is also working on the necessary stability testing for its drug product, which is crucial for the IND submission.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) has announced the receipt of four new patents, enhancing its intellectual property portfolio globally. In Japan, a patent for Stable Ready-to-Drink Beverage Compositions marks the 5th awarded in the country; in Australia, a patent for Enhanced Delivery of Antiviral Agents becomes the 10th. Canada has allowed a patent for Nicotine Compounds, and the USA has granted a patent for Treating Hypertension, crucial for future FDA applications. These patents underscore Lexaria's commitment to expanding its DehydraTECH technology, vital in the lucrative cardiovascular drugs market projected to grow from US$146.5 billion in 2022 to $173.5 billion by 2026. With these additions, Lexaria's patent portfolio increases to 32 granted patents worldwide.
FAQ
What is the current stock price of Lexaria Bioscience (LEXX)?
What is the market cap of Lexaria Bioscience (LEXX)?
